Whither the bone marrow transplant?

Hematology

Volumn 15, Issue 1, 2010, Pages 1-3

  Ruiz Argüelles, Guillermo J ^a  

^a CENTRO DE HEMATOLOGÍA Y MEDICINA INTERNA DE PUEBLA   (Mexico)

Author keywords

Bone marrow transplantation; Chronic myelogenous leukemia; Multiple myeloma

Indexed keywords

ALPHA INTERFERON; BORTEZOMIB; BUSULFAN; IMATINIB; LENALIDOMIDE; MELPHALAN; PROTEIN TYROSINE KINASE INHIBITOR; THALIDOMIDE;

ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; DRUG MEGADOSE; HEALTH CARE COST; HUMAN; MULTIPLE MYELOMA; NOTE; PRIORITY JOURNAL; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; DRUG COSTS; DRUG UTILIZATION; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MELPHALAN; MEXICO; MULTIPLE MYELOMA; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SPAIN; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; UNITED STATES;

EID: 76749134310     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453310X12583347009892     Document Type: Note

References (20)

1. Goldman J. Allogeneic stem cell transplantation for chronic myeloid leukemia. Status in 2007. Bone Marrow Transplant 2008; 42(Suppl 1): S11-S13.
2. Ruiz-Argüelles GJ, Gómez-Almaguer D, Morales-Toquero A et al. The early referral for reduced-intensity stem cell transplantation in patients with Ph1 (z) chronic myelogenous leukemia in chronic phase in the imatinib era: results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multicenter study. Bone Marrow Transplant 2005; 36: 1043-1047.
3. Ruiz-Argüelles GJ, Tar?́n-Arzaga LC, González-Carrillo ML et al. Therapeutic choices in patients with Ph1 (z) chronic myelogenous leukemia living in México in the tyrosine kinase inhibitors (TKI) era: stem cell transplantation or TKI's? Bone Marrow Transplant 2008; 42: 23-28.
4. Ruiz-Argüelles GJ, Gómez-Almaguer D, Ruiz-Argüelles A, González-Llano O, Cantú OG,Jaime-Pérez JC. Results of an outpatient-based stem cell allotransplant program using nonmyeloablative conditioning regimens. Am J Hematol 2001; 66: 241-244.
5. Ruiz-Argüelles GJ, Gómez-Almaguer D, López- Mart́nez B, Cantú-Rodŕguez OG, Jaime-Pérez JC, González-Llano O. Results of an allogeneic non-myeloablative stem cell transplantation program in patients with chronic myelogenous leukemia. Haematologica 2002; 87: 894-896.
6. Ruiz-Argüelles GJ, Gómez-Almaguer D. Making allogeneic bone marrow transplantation available to patients in developing countries: theMexican Experience. Open Hematol J 2008; 2: 30-36.
7. Gratwohl A, Baldomero H, Schwendener A, Gratwohl M, Urbano-Ispizua, Frauendorfer K. Hematopoietic stem cell transplants for chronic myeloid leukemia in Europe. Impact of cost considerations. Leukemia 2007; 21: 383-386.
8. Giralt SA, Arora M, Goldman JM et al. Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. Br J Haematol 2007; 137: 461-467.
9. Gratwohl A, Brand R, Apperley J et al. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006; 91: 513-521.
10. Gratwohl A, Baldomero H, Labar B, Apperley J, Urbano-Ispizua A, Accreditation Committee of the European Group for Blood and Marrow Transplantation (EBMT). Evolution of hematopoietic stem cell transplantation en Eastern and Western Europe from 1990 to 2003. A report from the EBMT activity survey. Croat Med J 2004; 45: 689-694. (Pubitemid 40052923)
11. Gajewski JL, Robinson P. Do affluent societies have the only option for the best therapy? Leukemia 2007; 21: 387-388.
12. Moynihan R. Key opinion leaders: Independent experts or drug representative in disguise? Brit Med J 2008; 336: 1402-1403.
13. Sox HC, Rennie D. Seeding trials: just say no. Ann Intern Med 2008; 149: 279-280.
14. Ruiz-Argüelles GJ, Gómez-Rangel D, Ruiz-Delgado GJ, Aguilar-Romero L. Multiple myeloma in México: a single institution, twenty-year experience. Arch Med Res 2004; 35: 163-167.
15. Kyle RA, Gertz MA, Witzig TE et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78: 21-33.
16. Alexanian R, Dimopoulos M. The treatment of multiple myeloma. N Engl J Med 1994; 330: 484-489.
17. López-Otero A, Ruiz-Delgado GJ, Ruiz-Argüelles GJ. A simplified method for stem cell autografting in multiple myeloma: a single institution experience. Bone Marrow Transplant 2009; 44(11): 715-719.
18. Thomas ED. Hematopoietic stem cell transplantation. Sci Am 1995; 272: 38-47.
19. Vela-Ojeda J, Garc?́a-Ruiz-Esparza MA, Padilla-Gonzalez Y et al. Autologous peripheral blood stem cell transplantation in multiple myeloma using oral versus I.V. melphalan. Ann Hematol 2007; 86: 277-282.
20. Fojo T, Grady C. How much is life worth: Cetuximab, non-small cell lung cancer and the $440 billion question. J Natl Cancer Inst 2009; 101: 1044-1048.